FDA grants fast track designation for Alzheimer’s treatment

The FDA has granted fast track designation for Vaxxinity Inc.’s UB-311, an anti-amyloid beta immunotherapeutic vaccine, for the treatment of Alzheimer’s disease.
UB-311 is an immunotherapeutic vaccine candidate, which targets toxic forms of amyloid beta in the brain, in order to treat Alzheimer’s disease. Phase 1, phase 2 and phase 2a long-term extension trials have shown UB-311 to be well-tolerated and safe in patients over 3 years of repeat dosing.
“We are excited that the FDA has granted UB-311 fast track designation, as it recognizes the evidence demonstrating the

The FDA has granted fast track designation for Vaxxinity Inc.’s UB-311, an anti-amyloid beta immunotherapeutic vaccine, for the treatment of Alzheimer’s disease.
UB-311 is an immunotherapeutic vaccine candidate, which targets toxic forms of amyloid beta in the brain, in order to treat Alzheimer’s disease. Phase 1, phase 2 and phase 2a long-term extension trials have shown UB-311 to be well-tolerated and safe in patients over 3 years of repeat dosing.
“We are excited that the FDA has granted UB-311 fast track designation, as it recognizes the evidence demonstrating the